Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford University and Kingsley Capital Partners have launched a new research programme to investigate the role of cannabinoids in biology and medicine.

© Shutterstock
Endocannabinoid signalling is increasingly recognised as fundamentally important in the development and function of the nervous system. This exciting programme of work has the potential to lead to the development of novel therapies for neurological disorders.’
- Associate Professor in Clinical Neurosciences, Zameel Cader

The programme aims to develop new therapies for acute and chronic conditions including pain, cancer and inflammatory disease.

Through an initial investment of up to £10 million provided by Kingsley, funded through its new portfolio company Oxford Cannabinoid Technologies (OCT), and a series of research projects performed by medical research teams, Oxford will seek to identify new medical therapies through research into the molecular, cellular and systems mechanisms of cannabinoids.

Read more...

Similar stories

New insights into the effect of exposure to dim light in the evening on the biology of the sleep-wake cycle

A new study has revealed more about how exposure to dim light in the evening affects circadian health. The findings emphasise the need to optimise our artificial light exposure if we are to avoid shifting our biological clocks.

Blood lipoprotein levels linked to future risk of amyotrophic lateral sclerosis

Greater understanding of the role of lipoproteins could support screening and efforts to develop treatments.

International study finds insomnia, anxiety and depression very prevalent during first phase of COVID-19 pandemic

Researchers are recommending public health interventions to reduce the long-term adverse outcomes associated with chronic insomnia and mental health problems.

Alexander Davies wins top UKRI Future Leaders Fellowship

Alex is one of eight Oxford University academics who have been awarded significant financial funding from the UKRI Future Leaders Fellowships Scheme

New study on link between autoimmunity and pain

Patients with autoantibodies which target neuronal proteins can have pain as an under-recognised clinical manifestation.